The company expects to obtain approval for obesity in the second half of 2026 and for diabetes in 2028, positioning the product as a long-term component of its metabolic disease portfolio
Umbrella Labs' internal teams are aggregating and re-analyzing existing literature to map where the current evidence converges, where methodological gaps exist, and where non-clinical bench studies can meaningfully clarify the peptide's behavior without venturing into clinical claim territory
Furthermore, partial Pearson correlations were estimated to assess whether changes in body weight were associated with changes in BMD, CTX, and P1NP
By raising moisture levels, it smooths and softens dry, dehydrated skin and helps retain and promote moisture
Januar 2026
Research to get Lillys pill approved by the FDA is expected to take four years from start to finish